




EMLc

ATC codes: [P01CC01](#)

| | |
|-------------------------|---|
| Indication | Chagas disease ICD11 code: 1F53.Z |
| INN | Nifurtimox |
| Medicine type | Chemical agent |
| List type | Core |
| Formulations | Oral > Solid: 30 mg tablet ; 120 mg tablet ; 250 mg tablet |
| EML status history | <p>First added in 1977 (TRS 615)</p> <p>Changed in 1979 (TRS 641)</p> <p>Changed in 1982 (TRS 685)</p> <p>Changed in 1987 (TRS 770)</p> <p>Changed in 2003 (TRS 920)</p> <p>Changed in 2007 (TRS 950)</p> |
| Sex | All |
| Age | Also recommended for children |
| Therapeutic equivalence | The recommendation is for this specific medicine |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  |
| Wikipedia | Nifurtimox  |
| DrugBank | Nifurtimox  |

Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee noted that as with treatments for African trypanosomiasis, older drugs are the mainstay of treatment for American trypanosomiasis (*Trypanosoma cruzi* infection). There is little information on the effectiveness and safety of nifurtimox. The Subcommittee noted a review indicating that the Ministries of Health in Latin America had accepted both agents as specific chemotherapeutic agents for *Trypanosoma cruzi* infection in adults and children, to eliminate the parasite from those infected and for breaking transmission. The Subcommittee therefore recommended that nifurtimox be endorsed for the EMLc for the treatment of American trypanosomiasis (*Trypanosoma cruzi* infection). The Subcommittee recognized the need to look at the efficacy and safety of these medicines in children for the next meeting. Also there was a need to develop paediatric-appropriate forms of these medicines.

